|
Marinomed Biotech AG / Key word(s): Insolvency/Restructure of Company Marinomed Biotech AG: Court opens restructuring proceedings without self-administration 14-Aug-2024 / 15:35 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Korneuburg, Austria, 14. August 2024 – Marinomed Biotech AG (VSE:MARI) announces that on August 14, 2024, the Regional Court of Korneuburg opened restructuring proceedings without self-administration at the request of Marinomed Biotech AG. The Company expects trading of Marinomed shares to resume soon and a switch to the standard market continuous on the Vienna Stock Exchange.
+++ End of ad-hoc announcement +++ End of Inside Information 14-Aug-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com |
Evaluating the top five sterilisation techniques for parenteral packaging – Pharmaceutical Technology
Share this article A wide range of physical and chemical sterilisation options are available to drug manufacturers. In this article, we evaluate five of the
November 15, 2023